Dr. Rozencweig is recognized as a world leading expert and opinion leader in medical oncology and anti-cancer drug development. He built and led the clinical research group at Bristol-Myers Squibb (“BMS”) that developed all the NCEs brought by BMS to the market from 1983 to 2001 in the area of cancer (including carboplatin and paclitaxel).
Under his leadership, a total of 17 marketing applications (NDAs or sNDAs1) were successfully filed by BMS in the area of cancer, HIV and infectious diseases.
Before joining the industry, Dr. Rozencweig pursued an academic career and currently serves as an Adjunct Associate Professor of Medicine at New York University, NY. He created and chaired a number of European groups (EORTC) devoted to multinational drug-oriented and disease-oriented trials (e.g., Early Clinical Trials Group).
Dr. Rozencweig is a medical doctor, graduated from the Université Libre de Bruxelles, in Belgium. Working part-time for Innate Pharma, he will be based in the US.
“We are very pleased to welcome Dr. Rozencweig in Innate Pharma’s team. His extensive experience in the development of cancer drugs, and his US perspective well complement the existing expertise within the company” said Hervé Brailly, Innate Pharma's CEO. He added: "His knowledge of the market and key opinion leaders will help us position our drugs and choose the optimal development path for registration in a complex and rapidly evolving environment". “Joining Innate Pharma is a very exciting opportunity: the Company has a unique portfolio of first-in-class drug candidates and contributing to their development will be a very stimulating challenge for me” said Dr. Rozencweig.
About Innate Pharma
Innate Pharma S.A. (the “Company”) is a clinical stage biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and other severe diseases. Founded in 1999, it was initially listed on NYSE-Euronext in Paris in 2006.
The Company has a significant expertise in bringing novel targets to the clinical proof-ofconcept trials of drug candidates. It currently has seven proprietary drug-candidates (two of which in clinical trials) and two programs out-licensed to Novo Nordisk A/S.
Based in Marseilles, France, Innate Pharma had 89 employees as at December 31, 2008. Learn more about Innate-Pharma at www.innate-pharma.com
